Rituximab increases sustained complete remission in patients with pemphigus vulgaris

1. A higher sustained complete remission rate was shown with rituximab treatment compared to mycophenolate mofetil in patients with pemphigus vulgaris. 2. Patients treated with...

Epidemiologic analysis of chilblains cohorts before and during the COVID-19 pandemic

1. The incidence of chilblains increased during the COVID-19 pandemic, but chilblains cases were only weakly associated with COVID-19 infection, with only 2.0% of...

Upadacitinib plus topical corticosteroids is safe and effective for moderate-to-severe atopic dermatitis

1. Upadacitinib combined with topical corticosteroids reduced Eczema Area and Severity Index (EASI) and Investigator’s Global Assessment for atopic dermatitis (vIGA-AD) scores significantly more...

Upadacitinib monotherapy is effective for patients with moderate-to-severe atopic dermatitis

1. The proportion of patients with EASI ≥75% was significantly greater in the upadacitinib 30 mg and 15 mg groups than the placebo group. 2....

Online modules for pediatricians on human papillomavirus communication strategies linked to increased HPV...

1. Online training for pediatricians on human papillomavirus (HPV) communication strategies is associated with an increase in rates of HPV vaccination, reducing missed opportunities...

Topical corticosteroid use in pregnancy not associated with increased risk of small for gestational...

1. No association was found between topical corticosteroid use during pregnancy and increased risks of newborns being small for gestational age (SGA) or having...

Diagnosis of atopic dermatitis in children may be associated with lower educational attainment

1. Individuals diagnosed with atopic dermatitis (AD) as children were at elevated risk of not attaining lower and upper secondary education, compared to the...

Bimekizumab superior to secukinumab for plaque psoriasis treatment

1. Bimekizumab treatment was shown to be noninferior and superior for greater skin clearance of plaque psoriasis compared to secukinumab treatment. 2. Bimekizumab treatment was...

Bimekizumab shows better efficacy in treating severe plaque psoriasis than ustekinumab

1. Bimekizumab showed higher efficacy in the treatment of severe plaque psoriasis than ustekinumab with patients showing greater proportion of PASI90 and IGA response. 2....

Bimekizumab is tolerable and efficacious for patients with moderate to severe plaque psoriasis

1. 91% of patients receiving bimekizumab 320 mg every 4 weeks achieved ≥ 90% improvement from baseline in the Psoriasis Area Severity Index (PASI90)...

All-time hits